The Valley Desk

ArticleAdvances in therapyPublished

FREEDOMM: Fifth-Line or Later Real-World Evaluation of Efficacy and Disease Outcomes in Multiple Myeloma with Ciltacabtagene Autoleucel: Treatment-Free Interval and Overall Survival in the USA

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
Advances in therapy
Published
Subject terms
Humans; Multiple Myeloma; Treatment Outcome; Aged; Middle Aged; United States; Female; Male; Bridge Therapy; Multiple myeloma; Clinical Outcomes; Overall Survival
PubMed ID
41874852
PubMed Central ID
PMC13156228
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal